After hosting an investor dinner with a gastroenterologist and a community primary care physician with "sizable and busy practices," Leerink analyst Puneet Souda is confident that penetration of Exact Sciences' Cologuard is "bound to ramp significantly higher from current levels." Both physicians expect colleagues and the broader referral-chain physicians to increase their Cologuard volumes significantly, Souda tells investors in a research note. The analyst thinks Cologuard adoption "should ramp strong" among primary care physicians around the country. Souda keeps an Outperform rating on Exact Sciences with a $67 price target.